Evolocumab use in Greece is associated with early and sustainable reductions in low-density cholesterol (LDL-C) and high persistence to therapy: Results from the Greek cohort analysis of the observational HEYMANS study

Hellenic J Cardiol. 2023 Nov-Dec:74:74-76. doi: 10.1016/j.hjc.2023.09.003. Epub 2023 Sep 18.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Anticholesteremic Agents* / therapeutic use
  • Cholesterol, LDL
  • Greece / epidemiology
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors* / therapeutic use
  • Proprotein Convertase 9
  • Treatment Outcome

Substances

  • evolocumab
  • Cholesterol, LDL
  • Antibodies, Monoclonal, Humanized
  • Anticholesteremic Agents
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Proprotein Convertase 9